Epidemiology of Wegener's granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinants

Clinical and Experimental Rheumatology

Volumn 24, Issue 2 SUPPL. 41, 2006, Pages

  Mahr, Alfred D ^a   Neogi, Tuhina ^a   Merkel, Peter A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Frequency; Genetics; Risk factor; Wegener's granulomatosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; CADMIUM; COTRIMOXAZOLE; HYDRALAZINE; LEAD; MERCURY; PESTICIDE; PROPYLTHIOURACIL; SILICON DIOXIDE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CAUCASIAN; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENVIRONMENT; GENETIC RISK; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HEREDITY; HUMAN; INCIDENCE; MIGRATION; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEASONAL VARIATION; URBAN RURAL DIFFERENCE; VASCULITIS; WEGENER GRANULOMATOSIS;

ALPHA 1-ANTITRYPSIN; DEMOGRAPHY; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGIC STUDIES; GENETIC PREDISPOSITION TO DISEASE; GEOGRAPHY; HUMANS; OCCUPATIONAL EXPOSURE; PREVALENCE; RISK FACTORS; SEASONS; SILICON DIOXIDE; WEGENER GRANULOMATOSIS;

EID: 33745684328     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. SEO P, STONE JH: The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117: 39-50.
2. van der WOUDE FJ, RASMUSSEN N, LOBATTO S et al.: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-9.
3. LEAVITT RY, FAUCI AS, BLOCH DA et al.: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
4. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
5. KURLAND LT, HAUSER WA, FERGUSON RH, HOLLEY KE: Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc 1969; 44: 649-63.
6. SCOTT DG, BACON PA, ELLIOTT PJ, TRIBE CR, WALLINGTON TB: Systemic vasculitis in a district general hospital 1972-1980: clinical and laboratory features, classification and prognosis of 80 cases. Q J Med 1982; 51: 292-311.
7. ANDREWS M, EDMUNDS M, CAMPBELL A, WALLS J, FEEHALLY J: Systemic vasculitis in the 1980s-is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis? J R Coll Physicians Lond 1990; 24: 284-8.
8. COTCH MF, HOFFMAN GS, YERG DE, KAUFMAN GI, TARGONSKI P, KASLOW RA: The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996; 39: 87-92.
9. CARRUTHERS DM, WATTS RA, SYMMONS DP, SCOTT DG: Wegener's granulomatosis-increased incidence or increased recognition? Br J Rheumatol 1996; 35: 142-5.
10. HAUGEBERG G, BIE R, BENDVOLD A, LARSEN AS, JOHNSEN V: Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 1998; 17: 364-8.
11. GONZALEZ-GAY MA, GARCIA-PORRUA C: Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore) 1999; 78: 292-308.
12. KOLDINGSNES W, NOSSENT H: Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 2000; 43: 2481-7.
13. WATTS RA, LANE SE, BENTHAM G, SCOTT DG: Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000; 43: 414-9.
14. REINHOLD-KELLER E, ZEIDLER A, GUTFLEISCH J, PETER HH, RASPE HH, GROSS WL: Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 2000; 39: 1396-402.
15. REINHOLD-KELLER E, HERLYN K, WAGNER-BASTMEYER R et al.: No difference in the incidences of vasculitides between north and south Germany: first results of the German Vasculitis Register. Rheumatology (Oxford) 2002; 41: 540-9.
16. GONZALEZ-GAY MA, GARCIA-PORRUA C, GUERRERO J, RODRIGUEZ-LEDO P, LLORCA J: The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49: 388-93.
17. MOHAMMAD A, JACOBSSON L, SEGELMARK M, STURFELT G: Prevalence of small vessel vasculitis in Sweden - preliminary report (abstract). Kidney Blood Press Res 2003; 26: S251.
18. MAHR A, GUILLEVIN L, POISSONNET M, AYMÉ S: Prevalence of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 5: 92-9.
19. REINHOLD-KELLER E, HERLYN K, WAGNER-BASTMEYER R, GROSS WL: Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005; 53: 93-9.
20. ZEFT A, SCHLESINGER M, WEISS N, EMERY H: Case control study of ANCA-associated vasculitis in Western Montana (abstract). Arthritis Rheum 2005; 52: S648.
21. KNIGHT A, EKBOM A, BRANDT L, ASKLING J: Increasing incidence of Wegener's granulomatosis in Sweden 1975-2001 (abstract). Arthritis Rheum 2005; 52: S403.
22. GIBSON A, STAMP LK, CHAPMAN PT, O'DONNELL JL: The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology (Oxford) 2006 (in press).
23. BRUCE IN, BELL AL: A comparison of two nomenclature systems for primary systemic vasculitis. Br J Rheumatol 1997; 36: 453-8.
24. LANE SE, WATTS RA, SHEPSTONE L, SCOTT DG: Primary systemic vasculitis: clinical features and mortality. Q J Med 2005; 98: 97-111.
25. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
26. ANDERSON G, COLES ET, CRANE M et al.: Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 1992; 83: 427-38.
27. MATTESON EL, GOLD KN, BLOCH DA, HUNDER GG: Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 1996; 101: 129-34.
28. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
29. STONE JH for the wegener's granulomatosis entanercept trial research group: Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003; 48: 2299-309.
30. BLIGNY D, MAHR A, TOUMELIN P, MOUTHON L, GUILLEVIN L: Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004; 51: 83-91.
31. WATTS RA, GONZALEZ-GAY MA, LANE SE, GARCIA-PORRUA C, BENTHAM G, SCOTT DG: Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60: 170-2.
32. WATTS RA, LANE SE, SCOTT DG et al.: Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001; 60: 1156-7.
33. WATTS RA, LANE S, SCOTT DG: What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 2005; 19: 191-207.
34. TIDMAN M, OLANDER R, SVALANDER C, DANIELSSON D: Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 1998; 244: 133-41.
35. FALK RJ, HOGAN S, CAREY TS, JENNETTE JC: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990; 113: 656-63.
36. RAYNAULD JP, BLOCH DA, FRIES JF: Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis. J Rheumatol 1993; 20: 1524-6.
37. BLOCKMANS D, VANDENBON C, MACKEN T, STEVENS E, BOBBAERS H: Wegener's granulomatosis: a study on 50 patients. Eur J Intern Med 1997; 8: 19-26.
38. DUNA GF, COTCH MF, GALPERIN C, HOFFMAN DB, HOFFMAN GS: Wegener's granulomatosis: role of environmental exposures. Clin Exp Rheumatol 1998; 16: 669-74.
39. MUNIAIN MA, MORENO JC, GONZALEZ CAMPORA R: Wegener's granulomatosis in two sisters. Ann Rheum Dis 1986; 45: 417-21.
40. KNUDSEN BB, JOERGENSEN T, MUNCH-JENSEN B: Wegener's granulomatosis in a family. A short report. Scand J Rheumatol 1988; 17: 225-7.
41. STONEY PJ, DAVIES W, HO SF, PATERSON IC, GRIFFITH IP: Wegener's granulomatosis in two siblings: a family study. J Laryngol Otol 1991; 105: 123-4.
42. HAY EM, BEAMAN M, RALSTON AJ, ACKRILL P, BERNSTEIN RM, HOLT PJ: Wegener's granulomatosis occurring in siblings. Br J Rheumatol 1991; 30: 144-5.
43. SEWELL RF, HAMILTON DV: Time-associated Wegener's granulomatosis in two members of a family. Nephrol Dial Transplant 1992; 7: 882.
44. ROTTEM M, COTCH MF, FAUCI AS, HOFFMAN GS: Familial vasculitis: report of 2 families. J Rheumatol 1994; 21: 561-3.
45. NOWACK R, LEHMANN H, FLORES-SUAREZ LF, NANHOU A, van der WOUDE FJ: Familial occurrence of systemic vasculitis and rapidly progressive glomerulonephritis. Am J Kidney Dis 1999; 34: 364-73.
46. MANGANELLI P, GIACOSA R, FIETTA P, ZANETTI A, NERI TM: Familial vasculitides: Churg-Strauss syndrome and Wegener's granulomatosis in 2 first-degree relatives. J Rheumatol 2003; 30: 618-21.
47. NAGIBOV VM, CHERANOV EA: A case of Wegener's granulomatosis in married couples (Russian). Vestn Otorinolaringol 1987: 72-3.
48. BARRETT TG, TAYLOR CM, THOMASON P, PALL A, ADU D: Environmental trigger for anti-neutrophil cytoplasmic antibodies? Lancet 1993; 342: 369-70.
49. ABDOU NI, KULLMAN GJ, HOFFMAN GS et al.: Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 2002; 29: 309-16.
50. WEINER SR, KWAN LW, PAULUS HE, CARO XJ, WEISBART RH: Twins discordant for Wegener's granulomatosis. Clin Exp Rheumatol 1986; 4: 389-90.
51. GASKIN G, PUSEY CD: Systemic vasculitis. In: DAVISON AM, CAMERON JS, GRÜNFELD JP, KERR DNS, RITZ E, WINEARLS CG, (Eds.): Oxford Textbook of Clinical Nephrology. Oxford, UK: Oxford University Press; 1996: 881-910.
52. BORGMANN S, HAUBITZ M: Genetic impact of pathogenesis and prognosis of ANCA-associated vasculitides. Clin Exp Rheumatol 2004; 22: S79-86.
53. JAGIELLO P, GROSS WL, EPPLEN JT: Complex genetics of Wegener's granulomatosis. Autoimmun Rev 2005; 4: 42-7.
54. STRIMLAN CV, TASWELL HF, KUEPPERS F, DEREMEE RA, McDONALD TJ: HLA-A antigens of patients with Wegener's granulomatosis. Tissue Antigens 1978; 11: 129-31.
55. MURTY GE, MAINS BT, MIDDLETON D, MAXWELL AP, SAVAGE DA: HLA antigen frequencies and Wegener's granulomatosis. Clin Otolaryngol Allied Sci 1991; 16: 448-51.
56. GRIFFITH ME, PUSEY CD: HLA genes in ANCA-associated vasculitides. Exp Clin Immunogenet 1997; 14: 196-205.
57. KATZ P, ALLING DW, HAYNES BF, FAUCI AS: Association of Wegener's granulomatosis with HLA-B8. Clin Immunol Immunopathol 1979; 14: 268-70.
58. BEIGEL A, LEHMANN H, WESTPHAL E: The spectrum of histocompatibility antigens (HLA) in Wegener's granulomatosis (German). Arch Otorhinolaryngol 1981; 233: 157-60.
59. COTCH MF, FAUCI AS, HOFFMAN GS: HLA typing in patients with Wegener's granulomatosis. Ann Intern Med 1995; 122: 635.
60. SPENCER SJ, BURNS A, GASKIN G, PUSEY CD, REES AJ: HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int 1992; 41: 1059-63.
61. PAPIHA SS, MURTY GE, AD'HIA A, MAINS BT, VENNING M: Association of Wegener's granulomatosis with HLA antigens and other genetic markers. Ann Rheum Dis 1992; 51: 246-8.
62. ELKON KB, SUTHERLAND DC, REES AJ, HUGHES GR, BATCHELOR JR: HLA antigen frequencies in systemic vasculitis: increase in HLA-DR2 in Wegener's granulomatosis. Arthritis Rheum 1983; 26: 102-5.
63. HAGEN EC, STEGEMAN CA, D'AMARO J et al.: Decreased frequency of HLA-DR13DR6 in Wegener's granulomatosis. Kidney Int 1995; 48: 801-5.
64. ESNAULT VL, TESTA A, AUDRAIN M et al.: Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993; 43: 1329-32.
65. ELZOUKI AN, SEGELMARK M, WIESLANDER J, ERIKSSON S: Strong link between the alpha 1-antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med 1994; 236: 543-8.
66. LHOTTA K, VOGEL W, MEISL T et al.: Alpha 1-antitrypsin phenotypes in patients with anti-neutrophil cytoplasmic antibody-positive vasculitis. Clin Sci (Lond) 1994; 87: 693-5.
67. SAVIGE JA, CHANG L, COOK L, BURDON J, DASKALAKIS M, DOERY J: Alpha 1-antitrypsin deficiency and anti-proteinase 3 antibodies in anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis. Clin Exp Immunol 1995; 100: 194-7.
68. BASLUND B, SZPIRT W, ERIKSSON S et al.: Complexes between proteinase 3, alpha 1-antitrypsin and proteinase 3 anti-neutrophil cytoplasm autoantibodies: a comparison between alpha 1-antitrypsin PiZ allele carriers and non-carriers with Wegener's granulomatosis. Eur J Clin Invest 1996; 26: 786-92.
69. GRIFFITH ME, LOVEGROVE JU, GASKIN G, WHITEHOUSE DB, PUSEY CD: C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 1996; 11: 438-43.
70. CALLEA F, GREGORINI G, SINICO A et al.: alpha 1-Antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: genetic and clinical implications. Eur J Clin Invest 1997; 27: 696-702.
71. ESNAULT VL, AUDRAIN MA, SESBOUE R: Alpha-1-antitrypsin phenotyping in ANCA-associated diseases: one of several arguments for protease/ antiprotease imbalance in systemic vasculitis. Exp Clin Immunogenet 1997; 14: 206-13.
72. BORGMANN S, ENDISCH G, URBAN S, SITTER T, FRICKE H: A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis. Clin Immunol 2001; 98: 244-8.
73. HUANG D, GISCOMBE R, ZHOU Y, LEFVERT AK: Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J Rheumatol 2000; 27: 397-401.
74. GISCOMBE R, WANG X, HUANG D, LEFVERT AK: Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener's granulomatosis. J Rheumatol 2002; 29: 950-3.
75. ZHOU Y, HUANG D, PARIS PL, SAUTER CS, PROCK KA, HOFFMAN GS: An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum 2004; 50: 2645-50.
76. MURAKÖZY G, GAEDE KI, RUPRECHT B et al.: Gene polymorphisms of immunoregulatory cytokines and angiotensin-converting enzyme in Wegener's granulomatosis. J Mol Med 2001; 79: 665-70.
77. ZHOU Y, GISCOMBE R, HUANG D, LEFVERT AK: Novel genetic association of Wegener's granulomatosis with the interleukin 10 gene. J Rheumatol 2002; 29: 317-20.
78. BÁRTFAI Z, GAEDE KI, RUSSELL KA, MURAKÖZY G, MÜLLER-QUERNHEIM J, SPECKS U: Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. Clin Immunol 2003; 109: 330-7.
79. GENCIK M, MELLER S, BORGMANN S, FRICKE H: Proteinase 3 gene polymorphisms and Wegener's granulomatosis. Kidney Int 2000; 58: 2473-7.
80. JAGIELLO P, ARIES P, ARNING L et al.: The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005; 52: 4039-43.
81. ZHOU Y, HUANG D, FARVER C, HOFFMAN GS: Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener's granulomatosis. J Rheumatol 2003; 30: 1541-7.
82. JAGIELLO P, GENCIK M, ARNING L et al.: New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 2004; 114: 468-77.
83. WEGENER F: Über eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr Pathol Anat Allg Pathol 1939: 36-68.
84. PINCHING AJ, REES AJ, PUSSELL BA, LOCKWOOD CM, MITCHISON RS, PETERS DK: Relapses in Wegener's granulomatosis: the role of infection. Br Med J 1980; 281: 836-8.
85. DeREMEE RA, McDONALD TJ, WEILAND LH: Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985; 60: 27-32.
86. STEGEMAN CA, TERVAERT JW, de JONG PE, KALLENBERG CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335: 16-20.
87. FAUCI AS, HAYNES BF, KATZ P, WOLFF SM: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
88. van PUTTEN JW, van HAREN EH, LAMMERS JW: Association between Wegener's granulomatosis and Staphylococcus aureus infection? Eur Respir J 1996; 9: 1955-7.
89. STEGEMAN CA, TERVAERT JW, SLUITER WJ, MANSON WL, de JONG PE, KALLENBERG CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann Intern Med 1994; 120: 12-7.
90. GORDON C, LUQMANI R, FIELDS P, HOWIE AJ, EMERY P: Two cases of 'Wegener's tuberculosis'. Br J Rheumatol 1993; 32: 143-9.
91. TOYOSHIMA M, CHIDA K, SUDA T, IMOKAWA S, NAKAMURA H: Wegener's granulomatosis responding to antituberculous drugs. Chest 2001; 119: 643-5.
92. KHILNANI GC, BANGA A, SHARMA SC, GUPTA SD: Wegener's granulomatosis: an isolated lung mass responding to antituberculosis therapy and atypical course. J Assoc Physicians India 2003; 51: 731-3.
93. HOFFMAN GS, SECHLER JM, GALLIN JI et al.: Bronchoalveolar lavage analysis in Wegener's granulomatosis. A method to study disease pathogenesis. Am Rev Respir Dis 1991; 143: 401-7.
94. NIKKARI S, MERTSOLA J, KORVENRANTA H, VAINIONPAA R, TOIVANEN P: Wegener's granulomatosis and parvovirus B19 infection. Arthritis Rheum 1994; 37: 1707-8.
95. CORMAN LC, STAUD R: Association of Wegener's granulomatosis with parvovirus B19 infection: comment on the concise communication by Nikkari et al. Arthritis Rheum 1995; 38: 1174-5.
96. EDEN A, MAHR A, SERVANT A et al.: Lack of association between B19 or V9 erythrovirus infection and ANCA-positive vasculitides: a case-control study. Rheumatology (Oxford) 2003; 42: 660-4.
97. NUYTS GD, Van VLEM E, De VOS A et al.: Wegener's granulomatosis is associated to exposure to silicon compounds: a case-control study. Nephrol Dial Transplant 1995; 10: 1162-5.
98. HOGAN SL, SATTERLY KK, DOOLEY MA, NACHMAN PH, JENNETTE JC, FALK RJ: Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol 2001; 12: 134-42.
99. STRATTA P, MESSUEROTTI A, CANAVESE C et al.: The role of metals in autoimmune vasculitis: epidemiological and pathogenic study. Sci Total Environ 2001; 270: 179-90.
100. LANE SE, WATTS RA, BENTHAM G, INNES NJ, SCOTT DG: Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 2003; 48: 814-23.
101. ALBERT D, CLARKIN C, KOMOROSKI J, BRENSINGER CM, BERLIN JA: Wegener's granulomatosis: Possible role of environmental agents in its pathogenesis. Arthritis Rheum 2004; 51: 656-64.
102. GREGORINI G, FERIOLI A, DONATO F et al.: Association between silica exposure and necrotizing crescentic glomerulonephritis with p-ANCA and anti-MPO antibodies: a hospital-based case-control study. Adv Exp Med Biol 1993; 336: 435-40.
103. BEAUDREUIL S, LASFARGUES G, LAUERIERE L et al.: Occupational exposure in ANCA-positive patients: a case-control study. Kidney Int 2005; 67: 1961-6.
104. STEENLAND K, GOLDSMITH DF: Silica exposure and autoimmune diseases. Am J Ind Med 1995; 28: 603-8.
105. CUADRADO MJ, D'CRUZ D, LLOYD M, MUJIC F, KHAMASHTA MA, HUGHES GR: Allergic disorders in systemic vasculitis: a case-controlled study. Br J Rheumatol 1994; 33: 749-53.
106. HAUBITZ M, WOYWODT A, de GROOT K, HALLER H, GOEBEL U: Smoking habits in patients diagnosed with ANCA associated small vessel vasculitis. Ann Rheum Dis 2005; 64: 1500-2.
107. TATSIS E, REINHOLD-KELLER E, STEINDORF K, FELLER AC, GROSS WL: Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum 1999; 42: 751-6.
108. PANKHURST T, SAVAGE CO, GORDON C, HARPER L: Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) 2004; 43: 1532-5.
109. PILLINGER M, STAUD R: Wegener's granulomatosis in a patient receiving propylthiouracil for Graves' disease. Semin Arthritis Rheum 1998; 28: 124-9.
110. CHOI HK, MERKEL PA, WALKER AM, NILES JL: Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43: 405-13.
111. MERKEL PA: Drug-induced vasculitis. Rheum Dis Clin North Am 2001; 27: 849-62.
112. WATTS RA, LANE SE, SCOTT DG, on behalf of EMEA vasculitis group: Towards a practical classification for vasculitis (abstract). Arthritis Rheum 2005; 52: S224.